naproxen has been researched along with cifenline in 2 studies
| Studies (naproxen) | Trials (naproxen) | Recent Studies (post-2010) (naproxen) | Studies (cifenline) | Trials (cifenline) | Recent Studies (post-2010) (cifenline) |
|---|---|---|---|---|---|
| 4,551 | 1,057 | 1,429 | 303 | 49 | 33 |
| Protein | Taxonomy | naproxen (IC50) | cifenline (IC50) |
|---|---|---|---|
| Sodium channel protein type 1 subunit alpha | Homo sapiens (human) | 7.8 | |
| Sodium channel protein type 4 subunit alpha | Homo sapiens (human) | 7.8 | |
| Sodium channel protein type 7 subunit alpha | Homo sapiens (human) | 7.8 | |
| Potassium voltage-gated channel subfamily H member 2 | Homo sapiens (human) | 8.8 | |
| Sodium channel protein type 5 subunit alpha | Homo sapiens (human) | 7.8 | |
| Sodium channel protein type 9 subunit alpha | Homo sapiens (human) | 7.8 | |
| Sodium channel protein type 2 subunit alpha | Homo sapiens (human) | 7.8 | |
| Sodium channel protein type 3 subunit alpha | Homo sapiens (human) | 7.8 | |
| Sodium channel protein type 11 subunit alpha | Homo sapiens (human) | 7.8 | |
| Sodium channel protein type 8 subunit alpha | Homo sapiens (human) | 7.8 | |
| Sodium channel protein type 10 subunit alpha | Homo sapiens (human) | 7.8 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Topliss, JG; Yoshida, F | 1 |
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
2 other study(ies) available for naproxen and cifenline
| Article | Year |
|---|---|
QSAR model for drug human oral bioavailability.
Topics: Administration, Oral; Biological Availability; Humans; Models, Biological; Models, Molecular; Pharmaceutical Preparations; Pharmacokinetics; Structure-Activity Relationship | 2000 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |